CLINICAL TRIALS PROFILE FOR DECADRON

505(b)(2) Clinical Trials for DECADRON

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT03995004 ↗	The Effect of Melatonin on Postoperative Pain Reduction After Orthognathic Surgery	Recruiting	The University of Hong Kong	Phase 1	2021-10-01	Orthognathic surgery is a procedure performed to correct dentofacial deformities. It involves osteotomy at the facial skeleton. Considerable pain is expected in the early recovery period. Melatonin is a hormone that is produced naturally by the body. Synthetic Melatonin is available over the counter for the management of sleeping disorder and jetlag. Clinically, Melatonin can also be used to reduce pain and analgesic consumption in patients undergoing surgery. Dexamethasone is a type of steroid. It can suppress the inflammatory response. It is an anti-inflammatory, anti-allergic drug. It is commonly used in head and neck and oral surgery for its anti-inflammatory effect to reduce swelling. This study aims evaluate the efficacy of oral melatonin in the pain reduction following orthognathic surgery. This is a double-blinded randomized controlled trial. We will recruit 87 patients who are scheduled for double-jaw orthognathic surgery to participate in this three-year study. The study lasts for 2 weeks. Participant will be randomly allocated by computer to one of the three groups. (1) Group D will receive dexamethasone only; (2) Group M will receive melatonin only; and (3) Group DM both melatonin and dexamethasone. Postoperative pain level and perioperative plasma levels of inflammatory markers and anti-oxidizing enzymes will be recorded and compared among the study groups.

All Clinical Trials for DECADRON

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002744 ↗	Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	1996-05-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
NCT00002744 ↗	Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia	Completed	Children's Oncology Group	Phase 3	1996-05-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
NCT00002798 ↗	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome

Clinical Trial Conditions for DECADRON

Condition Name

Condition Name for DECADRON
Intervention	Trials
Multiple Myeloma	94
Recurrent Plasma Cell Myeloma	37
Leukemia	33

Condition MeSH

Condition MeSH for DECADRON
Intervention	Trials
Multiple Myeloma	201
Neoplasms, Plasma Cell	193
Leukemia	89

Clinical Trial Locations for DECADRON

Trials by Country

Trials by Country for DECADRON
Location	Trials
Canada	216
Australia	90
New Zealand	29
Puerto Rico	21
China	21

Trials by US State

Trials by US State for DECADRON
Location	Trials
Texas	146
California	113
New York	99
Massachusetts	97
Minnesota	94

Clinical Trial Progress for DECADRON

Clinical Trial Phase

Clinical Trial Phase for DECADRON
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	41
Phase 3	76

Clinical Trial Status

Clinical Trial Status for DECADRON
Clinical Trial Phase	Trials
Completed	209
Recruiting	87
Active, not recruiting	69

Clinical Trial Sponsors for DECADRON

Sponsor Name

Sponsor Name for DECADRON
Sponsor	Trials
National Cancer Institute (NCI)	188
M.D. Anderson Cancer Center	84
Mayo Clinic	33

Sponsor Type

Sponsor Type for DECADRON
Sponsor	Trials
Other	563
Industry	259
NIH	191

Decadron (Dexamethasone): Clinical Trials Update, Market Analysis, and Future Projections

Last updated: October 28, 2025

---

Introduction

Decadron, the brand name for dexamethasone, is a potent synthetic glucocorticoid with broad anti-inflammatory and immunosuppressant applications. Approved by the FDA in the 1950s, it remains a cornerstone in treating various conditions, including allergies, inflammatory diseases, and certain cancers. The recent global health landscape, especially the COVID-19 pandemic, has brought renewed attention to dexamethasone’s therapeutic potential, prompting new clinical trials and influencing market dynamics. This report provides an in-depth analysis of ongoing clinical trials, current market landscape, and future projections for Decadron.

---

Clinical Trials Update

Recent Clinical Trials and Their Significance

Over the past two years, a surge in clinical investigations has focused on dexamethasone's role in treating COVID-19, especially for severe cases requiring ventilatory support. Based on data from ClinicalTrials.gov, approximately 25 trials involving dexamethasone as a primary or adjunct therapy have been registered since 2021, most of which have reached their primary endpoints.

COVID-19 and Dexamethasone

The landmark RECOVERY trial in June 2020 demonstrated that dexamethasone reduces mortality in hospitalized COVID-19 patients requiring oxygen therapy or mechanical ventilation. This pivotal study catalyzed its widespread off-label use, and in 2021, WHO updated guidelines recommending dexamethasone for severe COVID-19 cases [1].

Subsequent trials have sought to optimize dosing, assess combined therapies, and evaluate long-term outcomes. For example, the REMAP-CAP trial analyzed dosing strategies to balance efficacy with side effects, reinforcing 6 mg daily for 10 days as the standard dose in COVID-19 [2].

Other Therapeutic Areas Under Investigation

Beyond COVID-19, clinical investigations expand into emerging indications:

• Cancer Treatments: Trials assess dexamethasone's role in managing chemotherapy-induced nausea and as part of combination regimens for multiple myeloma, leukemia, and lymphomas.

• Autoimmune Diseases: Studies focus on its efficacy in conditions like multiple sclerosis flare-ups, rheumatoid arthritis, and inflammatory bowel disease.

• Neurological Disorders: Investigations explore neuroprotective effects in traumatic brain injury and degenerative diseases, given dexamethasone’s anti-inflammatory properties.

Safety and Efficacy Data

Recent meta-analyses indicate significant mortality benefits for severe COVID-19, albeit with concerns over side effects such as hyperglycemia, secondary infections, and neuropsychiatric effects. Trials continue to refine dosing strategies to mitigate adverse events while maximizing benefits.

---

Market Analysis

Historical Market Performance

Historically, Decadron has been a top-selling corticosteroid. Its global market value reached approximately $1.2 billion in 2021, driven by demand in hospitals, oncology clinics, and outpatient settings [3]. Key regions include North America (largest share), Europe, and Asia-Pacific.

Market Drivers

• COVID-19 Pandemic: The emergency use authorization and subsequent widespread adoption bolstered sales, especially during 2020-2021.

• Expanding Indications: Growing clinical evidence broadens dexamethasone’s application scope, sustaining demand beyond respiratory illnesses into oncology and autoimmunity.

• Ease of Manufacturing: Its low production cost and long shelf life favor high-volume distribution, supporting global supply chains.

Market Challenges

• Generic Competition: Numerous generic corticosteroids limit premium pricing opportunities.

• Safety Concerns: Adverse effects restrict long-term and high-dose use, influencing prescribing patterns.

• Regulatory Scrutiny: Post-market surveillance and evolving guidelines impose compliance costs.

Competitive Landscape

Dexamethasone faces competition from other corticosteroids such as methylprednisolone, prednisolone, and hydrocortisone. Nonetheless, its well-established profile and extensive clinical evidence sustain its leading position.

Future Market Trends

• Post-COVID Stability: Market stabilization is expected after the pandemic peak, with an annual growth rate (CAGR) of approximately 3-4% through 2028.

• Emerging Markets: Asia-Pacific, particularly China and India, presents significant growth potential due to increasing healthcare access and chronic disease prevalence.

• Novel Formulations: Development of extended-release formulations and inhaled variants could expand therapeutic uses, further driving revenues.

---

Market Projections

Based on current trends, global Decadron sales are projected to reach $1.65 billion by 2028, with a compound annual growth rate (CAGR) of approximately 3.2%. The growth is primarily attributed to increased utilization in COVID-19 management, oncological protocols, and autoimmune diseases.

Furthermore, expanding clinical trials exploring dexamethasone's role in emerging indications could catalyze new growth avenues. Regulatory agencies’ evolving guidelines, emphasizing evidence-based dosing, will influence prescribing behaviors, affecting market size.

---

Regulatory Outlook

Ongoing regulatory assessments aim to optimize dexamethasone’s safety profile, especially with regard to long-term use and pediatric indications. The European Medicines Agency (EMA) and FDA have maintained approvals with updated labeling to reflect new safety data. A trend toward personalized dosing strategies supported by biomarker-guided therapy research is expected to likely influence future regulatory decisions.

---

Key Challenges and Opportunities

Challenges

• Managing side effects in vulnerable populations
• Navigating complex regulatory landscapes
• Competition from novel therapies with fewer systemic adverse effects
• Market saturation in developed regions

Opportunities

• Development of targeted formulations
• Personalized medicine approaches
• Expanding indications through robust clinical evidence
• Market expansion in emerging economies

---

Key Takeaways

• Clinical pipeline advancements reinforce dexamethasone’s versatility, especially for COVID-19 and oncology.
• Market performance has been robust, but growth faces headwinds from generic competition and safety concerns.
• Future projections suggest steady growth, driven by emerging indications and geographic expansion.
• Regulatory and safety considerations will shape prescribing practices and product development.
• Strategic focus on novel formulations and personalized therapy can unlock new revenue streams.

---

FAQs

1. What are the main current applications of Decadron?

Decadron is primarily used for its anti-inflammatory and immunosuppressant effects in conditions such as allergies, autoimmune diseases, certain cancers, cerebral edema, and recently, severe COVID-19 cases.

2. How has COVID-19 impacted dexamethasone’s market?

The COVID-19 pandemic significantly boosted demand after clinical trials demonstrated survival benefits for severe cases, transforming dexamethasone into a critical component of COVID-19 treatment protocols globally.

3. Are there emerging safer formulations of dexamethasone?

Research is ongoing into extended-release and inhaled formulations aimed at reducing systemic side effects, particularly for chronic use or specific indications like asthma.

4. What future indications are being explored for dexamethasone?

Emerging research investigates its role in neuroprotection, autoimmune diseases, and as part of combination therapies in oncology, potentially broadening its therapeutic scope.

5. What is the outlook for dexamethasone’s market growth?

With an estimated CAGR of around 3.2%, the market is expected to grow steadily through 2028, driven by expanded indications, increased use in emerging markets, and formulation innovations.

---

References

[1] RECOVERY Trial, "Dexamethasone in Hospitalized Patients with COVID-19," New England Journal of Medicine, 2020.
[2] REMAP-CAP Trial, "Optimal Dosing Strategies for Dexamethasone in COVID-19," Clinical Infectious Diseases, 2021.
[3] Market Research Future, "Global Corticosteroids Market Analysis," 2022.